Abstract: A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.

Abstract: A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.

Abstract: In a multi-channel electrical communication system 1, a method of estimating the interference level in a test channel due to the intermodulation of two or more other channels, where each channel is centred upon a carrier frequency. The method comprises, for a given m-th order mode, an initial step of identifying the set(s) of carrier frequencies, the m-th order linear combination of which gives rise substantially to the carrier frequency of said test channel. This process is carried out by a computer 2. For the or each of the identified set of carrier frequencies, signal generators 3 are tuned to respective ones of the carrier frequencies. The generated signals are applied to an input of the communication system 1, and the intermodulation interference at the carrier frequency of the test channel is measured at an output of the system 1.

Abstract: An amplifier comprising an emitter-coupled pair of transistors having inductive load impedances, with capacitive feedback elements tuned with the inductive loads and the capacitive input of the following stage to be resonant at the range of frequencies to be amplified. The reactive loads and feedback elements introduce less noise than with resistive components.

Abstract: 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate is provided. This salt has high water solubility and thus advantageously allows parenteral administration in the form of a sterile aqueous solution suitable for injection.

Abstract: Compounds of Formula I are novel and useful as cardiovascular agents, particularly anti-arrhythmic agents: ##STR1## or the 5-imino-tautomer thereof or a salt of either, wherein R.sup.1 is C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl or C.sub.3-10 cycloalkyl, any of which is optionally substituted, and R.sup.2 to R.sup.6 are independently selected from hydrogen, halogen atom, C.sub.1-6 alkyl, alkenyl or alkynyl (all optionally substituted by one or more of halogen, hydroxy and aryl, amino, mono- or di-substituted amino, alkoxy (optionally substituted by one or more of halogen, hydroxy and aryl), alkenyloxy, aryl, acyloxy, cyano, nitro, aryl and alkylthio groups or any adjacent two of R.sup.2 to R.sup.6 are linked to form a (--CH.dbd.CH--CH.dbd.CH--) group.

Abstract: The present invention provides compounds of the formula (III): ##STR1## or an acid addition salt thereof, wherein R.sup.6 is chlorine, bromine, iodine, C.sub.1-4 alkyl or trifluoromethyl, or R.sup.6 and R.sup.7 from a --CH.dbd.CH--CH.dbd.CH-- group optionally substituted by a halogen atom or a C.sub.1-4 alkyl or trifluoromethyl group, R.sup.8 is hydrogen, bromine, iodine, C.sub.1-4 alkyl or trifluoromethyl, R.sup.9 is hydrogen, halogen, C.sub.1-4 alkyl or trifluoromethyl, R.sup.10 is hydrogen, methyl or fluorine and R.sup.11 is amino, C.sub.1-10 acylamino or di-substituted aminomethyleneamino provided that, at most, only two of R.sup.7 -R.sup.10 are other than hydrogen and that R.sup.7 -R.sup.10 are not all hydrogen when R.sup.6 is chlorine. Also provided are pharmaceutical compositions containing compounds of the formula (III), the first medical use of compounds of the formula (III), a process for preparing such compounds and intermediates through which this process proceeds.

Abstract: The present invention provides compounds of the formula (III): ##STR1## or an acid addition salt thereof, wherein R.sup.6, R.sup.7, R.sup.9 and R.sup.10 are each hydrogen, halogen, C.sub.1-4 alkyl or trifluoromethyl and R.sup.8 is chlorine or R.sup.7 and R.sup.8 are linked to form a --CH.dbd.CH--CH.dbd.CH-- group when one of R.sup.6 and R.sup.10 is other than hydrogen provided that when R.sup.8 is chlorine R.sup.6, R.sup.7, R.sup.9 and R.sup.10 are not all hydrogen atoms and that any one of R.sup.6, R.sup.7, R.sup.9 and R.sup.10 is not chlorine when the other three groups are hydrogen. Also provided are pharmaceutical compositions containing compounds of the formula (III), the first medical use of compounds of the formula (III), a process for preparing such compounds and intermediates through which this process proceeds.

Abstract: The present invention provides compounds of the formula (III): ##STR1## or an acid addition salt thereof, wherein R.sup.6 is chlorine, bromine, iodine, C.sub.1-4 alkyl or trifluoromethyl, or R.sup.6 and R.sup.7 form a --CH.dbd.CH--CH.dbd.CH--group optionally substituted by a halogen atom or a C.sub.1-4 alkyl or trifluoromethyl group, R.sup.8 is hydrogen, bromine, iodine, C.sub.1-4 alkyl or trifluoromethyl, R.sup.9 is hydrogen, halogen, C.sub.1-4 alkyl or trifluoromethyl, R.sup.10 is hydrogen, methyl or fluorine and R.sup.11 is amino, C.sub.1-10 acylamino or di-substituted aminomethyleneamino provided that, at most, only two of R.sup.7 -R.sup.10 are other than hydrogen and that R.sup.7 -R.sup.10 are not all hydrogen when R.sup.6 is chlorine. Also provided are pharmaceutical compositions containing compounds of the formula (III), the first medical use of compounds of the formula (III), a process for preparing such compounds and intermediates through which this process proceeds.

Abstract: The medical use of compounds of the formula (III): ##STR1## or pharmaceutically acceptable and addition salts thereof, wherein R.sup.6 is a hydrogen atom, R.sup.5 is a chlorine atom and R.sup.7 is a hydrogen or chlorine atom or R.sup.7 is a chlorine atom, R.sup.5 is a hydrogen atom and R.sup.6 is a chlorine atom, particularly for the treatment of CNS disorders, is disclosed. Solid pharmaceutical compositions are also described.